Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
DHMEQ targets the nuclear factor kappaB pathway to fight cancer
April 7th, 2005
DHMEQ targets the nuclear factor kappaB pathway to fight cancer. According to researchers in Japan, "we previously designed and synthesized the new nuclear factor kappaB (NF-kappaB) inhibitor dehydroxymethylepoxyquino-micin (DHMEQ) derived from the structure of the antibiotic epoxyquinomicin C. We looked into the effect of DHMEQ on cellular phenotypes and tumor growth in mice injected with human breast carcinoma cell line MDA-MB-231 or MCF-7. In estrogen-independent breast adenocarcinoma cell line MDA-MB-231, NF-kappaB is constitutively activated." "The addition of DHMEQ (10 mcg/mL) completely inhibited the activated NF-kappaB for at least 8 hours....
Source: Women's Health Weekly (2005-04-07)
|
